Immuneering (IMRX) Change in Receivables (2020 - 2023)
Immuneering (IMRX) recorded quarterly Change in Receivables of -$1046.0 in Q2 2023, up 90.8% quarter-over-quarter from -$11371.0 in Q1 2023, and up 98.97% on a YoY basis from -$525.72 in Q2 2022.
Immuneering (IMRX) Change in Receivables (2020 - 2023) Analysis & Trends
Immuneering's Change in Receivables history runs 4 years deep, the most recent figure standing at -$1046.0 for Q2 2023.
- In Q2 2023, Change in Receivables rose 98.97% year-over-year to -$1046.0; the TTM figure through Mar 2024 stood at -$1046.0 (up 99.62% YoY), while the FY2023 annual figure was -$12417.0, up 94.69% from the prior year.
- Change in Receivables was -$1046.0 for Q2 2023 at Immuneering, up from -$11371.0 in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $278185.0 in Q3 2020 to a low of -$250978.0 in Q4 2021.
- Historically, Change in Receivables has averaged -$27133.6 across 4 years, with a median of -$17550.5 in 2021.
- Biggest YoY gain for Change in Receivables was 535.73% in 2022; the steepest drop was 3847.7% in 2022.
- A 4-year view of Change in Receivables shows it stood at -$78035.0 in 2020, then sank by 221.62% to -$250978.0 in 2021, then surged by 76.98% to -$57763.0 in 2022, then soared by 98.19% to -$1046.0 in 2023.
- The last three Change in Receivables figures came in at -$1046.0 (Q2 2023), -$11371.0 (Q1 2023), and -$57763.0 (Q4 2022), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 22,529.00 |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | -39.80 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -4.08 Mn |
| 10 | Immuneering | 255.40 Mn | 255.40 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | -1,046.00 |
| Jun 30, 2023 | -1,046.00 |
| Mar 31, 2023 | -11,371.00 |
| Mar 31, 2023 | -11,371.00 |
| Dec 31, 2022 | -57,763.00 |
| Dec 31, 2022 | -57,763.00 |
| Sep 30, 2022 | -108,245.00 |
| Sep 30, 2022 | -108,245.00 |
| Jun 30, 2022 | -101,188.00 |
| Jun 30, 2022 | -101,188.00 |
| Mar 31, 2022 | 33,573.00 |
| Mar 31, 2022 | 33,573.00 |
| Dec 31, 2021 | -250,978.00 |
| Dec 31, 2021 | -250,978.00 |
| Sep 30, 2021 | -23,730.00 |
| Sep 30, 2021 | -23,730.00 |
| Jun 30, 2021 | 2,700.00 |
| Jun 30, 2021 | 2,700.00 |
| Mar 31, 2021 | -7,705.00 |
| Mar 31, 2021 | -7,705.00 |